Reihaneh Alsadat Mahmoudian1, Mohammad Reza Abbaszadegan2, Mohammad Mahdi Forghanifard3, Meysam Moghbeli1, Faezeh Moghbeli4, Jamshidkhan Chamani5, Mehran Gholamin6. 1. Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Medical Genetics Research Center, Medical School, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran. 4. Department Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran. 5. Faculty of Sciences, Department of Biochemistry and Biophysics, Mashhad Branch, Islamic Azad University, Mashhad, Iran. 6. Immunology Research Center, BuAli Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract
BACKGROUND: Human Cripto-1, a member of the EGF-CFC family, is involved in embryonic development, embryonic stem cell maintenance, and tumor progression. It also participates in multiple cell signaling pathways including Wnt, Notch, and TGF-β. Remarkably, it is expressed in cancer stem cell (CSC) compartments, boosting tumor cell migration, invasion, and angiogenesis. Although Cripto-1 is overexpressed in a variety of human malignant tumors, its expression in esophageal squamous cell carcinoma (ESCC) remains unclear. Our aim in this study was to evaluate the possible oncogenic role of Cripto-1 in ESCC progression and elucidate its association with clinicopathological parameters in patients. METHODS: In this study, Cripto-1 expression in 50 ESCC tissue samples was analyzed and compared to corresponding margin-normal esophageal tissues using quantitative real-time PCR. RESULTS: Cripto-1 was overexpressed in nearly 40% of ESCC samples compared with normal tissue samples. Significant correlations were observed between Cripto-1 expression and tumor differentiation grade, progression stage, and location (p < 0.05). CONCLUSIONS: Our results indicate that overexpression of Cripto-1 is involved in the development of ESCC. Further assessment will be necessary to determine the role of Cripto-1 cross talk in ESCC tumorigenesis.
BACKGROUND:Human Cripto-1, a member of the EGF-CFC family, is involved in embryonic development, embryonic stem cell maintenance, and tumor progression. It also participates in multiple cell signaling pathways including Wnt, Notch, and TGF-β. Remarkably, it is expressed in cancer stem cell (CSC) compartments, boosting tumor cell migration, invasion, and angiogenesis. Although Cripto-1 is overexpressed in a variety of humanmalignant tumors, its expression in esophageal squamous cell carcinoma (ESCC) remains unclear. Our aim in this study was to evaluate the possible oncogenic role of Cripto-1 in ESCC progression and elucidate its association with clinicopathological parameters in patients. METHODS: In this study, Cripto-1 expression in 50 ESCC tissue samples was analyzed and compared to corresponding margin-normal esophageal tissues using quantitative real-time PCR. RESULTS: Cripto-1 was overexpressed in nearly 40% of ESCC samples compared with normal tissue samples. Significant correlations were observed between Cripto-1 expression and tumor differentiation grade, progression stage, and location (p < 0.05). CONCLUSIONS: Our results indicate that overexpression of Cripto-1 is involved in the development of ESCC. Further assessment will be necessary to determine the role of Cripto-1 cross talk in ESCC tumorigenesis.
Entities:
Keywords:
Cancer stem cell; Cripto-1; ESCC; Expressional analysis; Real-time PCR
Authors: Caterina Bianco; Luigi Strizzi; Aasia Rehman; Nicola Normanno; Christian Wechselberger; Youping Sun; Nadia Khan; Morihisa Hirota; Heather Adkins; Kevin Williams; Richard U Margolis; Michele Sanicola; David S Salomon Journal: Cancer Res Date: 2003-03-15 Impact factor: 12.701
Authors: Kazuhide Watanabe; Matthew J Meyer; Luigi Strizzi; Joseph M Lee; Monica Gonzales; Caterina Bianco; Tadahiro Nagaoka; Shahram S Farid; Naira Margaryan; Mary J C Hendrix; Barbara K Vonderhaar; David S Salomon Journal: Stem Cells Date: 2010-08 Impact factor: 6.277
Authors: Luigi Strizzi; Lynne-Marie Postovit; Naira V Margaryan; Elisabeth A Seftor; Daniel E Abbott; Richard E B Seftor; David S Salomon; Mary J C Hendrix Journal: Breast Dis Date: 2008
Authors: F Francescangeli; P Contavalli; M L De Angelis; M Baiocchi; G Gambara; A Pagliuca; A Fiorenzano; C Prezioso; A Boe; M Todaro; G Stassi; N P Castro; K Watanabe; D S Salomon; R De Maria; G Minchiotti; A Zeuner Journal: Cell Death Differ Date: 2015-03-20 Impact factor: 15.828
Authors: Leorik Pereira Silva; Luiz Arthur Barbosa da Silva; Bruno Tavares Sedassari; Suzana Cantanhede Orsini Machado de Sousa; Joabe Dos Santos Pereira; Lélia Batista de Souza; Márcia Cristina da Costa Miguel Journal: Eur Arch Otorhinolaryngol Date: 2018-03-29 Impact factor: 2.503
Authors: Federica Francescangeli; Maria Laura De Angelis; Rachele Rossi; Giovanni Sette; Adriana Eramo; Alessandra Boe; Ombretta Guardiola; Tao Tang; Shi-Cang Yu; Gabriella Minchiotti; Ann Zeuner Journal: Front Oncol Date: 2022-06-02 Impact factor: 5.738